Doxercalciferol is a synthetic vitamin D2 analog used to treat secondary hyperparathyroidism in patients with chronic kidney disease with or without therapy of dialysis. Doxercalciferol is a synthetic vitamin D2 analog that undergoes metabolic activation in vivo to form 1α,25-dihydroxyvitamin D2 (1α,25-(OH)2D2), a naturally occurring, biologically active form of vitamin D2.
- Mechanism
- Curator reviewed
Calcitriol (1α,25-(OH)2D3) and 1α,25-(OH)2D2 regulate blood calcium at levels required for essential body functions. Specifically, the biologically active vitamin D metabolites control the intestinal absorption of dietary calcium, the tubular reabsorption of calcium by the kidney and, in conjunction with parathyroid hormone (PTH), the mobilization of calcium from the skeleton. They act directly on bone cells (osteoblasts) to stimulate skeletal growth, and on the parathyroid glands to suppress PTH (parathyroid hormone) synthesis and secretion. These functions are mediated by the interaction of these biologically active metabolites with specific receptor proteins in the various target tissues. In patients with chronic kidney disease (CKD), deficient production of biologically active vitamin D metabolites (due to lack of or insufficient 25-hydroxyvitamin D-1-alpha-hydroxylase activity) leads to secondary hyperparathyroidism, which contributes to the development of metabolic bone disease.
- Primary indication
- Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, as well as for the treatment of secondary hyperparathyroidism in patients with Stage 3 or Stage 4 chronic...Curator reviewed · 3 structured indications
- Formula / weight
- C28H44O2 · 412.6478 g/mol (avg)
- First approval
- Canada, 2007 · United States, 2006
- Also known as
- 1-Hydroxyergocalciferol · 1-Hydroxyvitamin D2 · 1α-hydroxyvitamin D2
- Code names
- BRN 4716774 · GZ427397 · TSA-840
- Brand names
Resolves to
HKXBNHCUPKIYDM-CGMHZMFXSA-NSMILES[H][C@@]1(CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C)[C@H](C)\C=C\[C@H](C)C(C)CWhat you can answer from here — as of June 19, 2026
Which drugs share a target with Doxercalciferol, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account